Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ Научный центр психического здоровья РАМН, Москва; 2ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Список исп. литературыСкрыть список 1. Akiskal HS, Akiskal KK, Radwan F et al. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Dis 2005; 85 (1–2): 3–16. 2. Bryant RA, Friedman MJ, Spiegel D et al. A review of acute stress disorder in DSM-V. Depres Anxiety 2011; 28 (9): 802–17. 3. Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 2012; 22 (Suppl. 3): 505–10. 4. Kasper S, Hajak G. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiat 2010; 71 (2): 109–20. 5. Kasper S, Corruble E. Antidepressant efficacy of agomelatine vs SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Intern Clin Psychopharmacol 2013; 28 (1): 12–9. 6. Lam RW et al. Fatigue and occupational functioning in major depressive disorder. Austral New Zealand J Psychiat 2013. 7. McKnight et al. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 2009; 29 (3): 243. 8. Mojtabai R. Bereavement-related depressive episodes: characteristics, 3-year course, and implications for the DSM-V. Arch Gen Psychiat 2011; 68 (9): 920–8. 9. Nierenberg AA, Alpert JE, Pava J et al. Course and treatment of atypical depression. J Clin Psychiat 1998; 59 (Suppl. 18): 5–9. 10. Norman TR. Agomelatine, melatonin and depressive disorder. Exp Opin Investig Drugs 2013; 22 (4): 407–10. 11. Pompili M, Serafini G. Agomelatine: a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiat 2013. 12. Quera-Salva MA, Hajak G. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Intern Clin Psychopharmacol 2011; 26 (5): 252–62. 13. Stein DJ, Picarel-Blanchot F. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Human Psychopharmacol 2013; 28 (2): 151–9. 14. Vaillant GE. Positive mental health: is there a cross-cultural definition? World Psychiat 2012; 11: 93–9. 15. Wakefield JC, Schmitz MF. Normal vs disordered bereavement-related depression: are the differences real or tautological? Acta Psychiat Scand 2013; 127 (2): 159–68. 16. Demyttenaere K, Corruble E. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine vs escitalopram, fluoxetine, and sertraline. CNS Spectrum 2013; 18 (3): 163–70.